Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance

Citius Pharmaceuticals IncTrade
YieldMax Magnificent 7 Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Citius Pharmaceuticals Inc trades at $0.68 (market cap $20.01M), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.28. Which is the better fit depends on your goals.

CTXRYMAG
Market Cap
$20.01M
Sector
HealthIncome / Options Overlay
52-Week High
$1.82$15.98
52-Week Low
$0.48$10.76
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG trades at $11.33, down 2.24% today, with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, with recent payments ranging from $0.07 to $0.40 per share. Technical indicators show strong trend momentum with ADX readings above 25, while RSI suggests potential overbought conditions on shorter timeframes.

YMAG's option income strategy generates substantial distributions but faces NAV stability challenges during earnings periods. The fund's structure effectively monetizes volatility in rangebound markets, though concentrated exposure to Magnificent Seven stocks creates single-sector risk. Current price action tests key support at $11-$12 resistance levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.

Read more on YMAG